Does Andrew Witty’s exit from GlaxoSmithKline signal the end for socially responsible drug pricing?

April 8, 2016

On March 31st, GlaxoSmithKline announced that it would give poorer countries cheap access to cancer drugs. It was the latest initiative from a company that, under CEO, Andrew Witty, had been ready to ask some of the hard questions of the pharmaceutical industry business model. But it seems that some of the defenders of the status quo may have won, for Witty is to step down from the top job next year. So is it back to business as usual from now on?

The short quote from Andrew Witty included in this episode comes from the longer interview by Bloomberg at https://www.youtube.com/watch?v=VSKwNQ7iugg
00:0000:00

Facebook Comments: